Recent News

• 06.04.2026 - Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
• 06.03.2026 - Madrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026
• 05.27.2026 - Madrigal Presents Data Demonstrating Rezdiffra Reduced Markers of Cardiovascular and Liver-Related Risk in Patients with MASH
• 05.21.2026 - Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
• 05.20.2026 - Madrigal to Present New Data from the Company’s MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension Risk
• 05.07.2026 - Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
• 05.06.2026 - Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates
• 05.05.2026 - Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline

Recent Filings

• 06.01.2026 - 144 Report of proposed sale of securities
• 06.01.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.22.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.22.2026 - 144 Report of proposed sale of securities
• 05.18.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.18.2026 - 144 Report of proposed sale of securities
• 05.15.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.15.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.06.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.06.2026 - 8-K Current report